Foundations in Immunotherapy in the Oncology Population: Strategies for Clinical Application and Patient Management

Immunotherapeutics have transformed the treatment landscape for patients with both solid tumors and hematologic malignancies. Since the landmark approval of ipilimumab, rapid and ongoing advancements in immunotherapy have continued to revolutionize clinical practice.

This one-day live virtual CME program will provide a comprehensive review of foundational concepts and emerging advances in cancer immunotherapy, tailored to the educational needs of physicians, advanced practice providers (APPs), and allied health professionals. Faculty experts will highlight clinical applications across solid and hematologic cancers, as well as strategies for recognizing and managing toxicity—including immune-related adverse events (irAEs) associated with immune checkpoint inhibition.

Presentations will cover the fundamentals of immune checkpoint blockade and CAR T-cell therapy, along with updates in TIL and BiTE therapies, novel combination approaches, and algorithmic management of irAEs. Toxicity management will be reinforced through case-based discussions illustrating common, rare, and severe presentations.

The goal of this program is to improve patient outcomes by advancing understanding of cancer immunology and enhancing the effective, evidence-based application of immunotherapeutic strategies in clinical practice.

Participants will receive access to an online syllabus after the symposium concludes, which will include video recordings of the faculty presentations. Please note that PDFs of the speakers’ presentations will not be included.

1. Identify and define foundational concepts of immunotherapy, including key immune system components, mechanisms of action, and types of immunotherapeutic agents.
2. Explain the biological rationale and mechanisms by which immunotherapy targets solid and hematologic malignancies, distinguishing between innate and adaptive immune responses.
3. Apply evidence-based immunotherapeutic approaches to the management of solid tumors and hematologic cancers, including appropriate patient selection, risk stratification, and development of individualized treatment plans.
4. Compare and contrast novel immunotherapy agents, including checkpoint inhibitors, bispecific antibodies, and immune agonists, in terms of efficacy, safety profiles, and mechanisms of action.
5. Evaluate the role of CAR T-cell therapy in current oncology practice, including patient eligibility, response rates, and long-term outcomes, and design a toxicity management plan for immune-related adverse events (irAEs) in immuno-oncology patients.

This program will be held virtually via Zoom. Detailed access instructions will be provided prior to the start of the program.

Registration Fees

• Physicians (MDs, PhDs, and DOs): $249

• Advanced Practice Providers: $199

• Nurses: $149

• Residents, Fellows, and Trainees: $25*

• Industry Professionals: $435**

• MSK Employees: Complimentary

*The registration fee for residents, fellows, and trainees is non-refundable.
**An “industry professional” is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. Please review our Registration Policy for Industry Professionals for more information.

Registration Discounts: Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our policy on Registration Discounts for more information.

Cancellation Policy: For details on our cancellation terms, please review our Cancellation Policy.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Symposium Director

Mary Kate Kasler, MSN, RN, DNP, ACNP-BC

Symposium Co-Directors

Sandra D’Angelo, MD

Kerry Williams, MSN, RN, ANP-BC, AOCNP®

Symposium Planning Committee 

Linda D’Andrea, MSN, RN, PPCNP-BC, CPHON®
Madeline Merrill, MSN, RN, AGNP-BC
Yelena Shames, MSN, RN, ACNP-BC, CNRN®
Caroll Tipian, MSN, RN, DNP, AGACNP-BC
Joanne Wells, MSN, RN, ANP-BC, AOCNP®

MSK Faculty 

Gabrielle Arauz, MSN, RN, AGNP-BC, OCN®
Lauren Baker Banks, MD, PhD
Claudia Calderon, MSN, RN, AGPCNP-BC, OCN®
Joshua Drago, MD, MS
Ross Firestone, MD, PhD
Lynnette Henshaw, PharmD
Liubou Korzun, PA-C
Melanie Melendez, MSN, RN, AGPCNP-C, AOCNP®
Lavanya Mittal, MD
Katherine Nagel, MSN, RN, FNP-BC
Roisin O'Cearbhaill, MD
Rebecca Repetti, MSN, RN, ANP-BC, AOCNP®
Bianca Santomasso, MD, PhD
Alexander Shoushtari, MD
James Smithy, MD, MHS
Alice Wang, PharmD
Jessica Wilcox, MD

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Wednesday, January 28, 2026